Use of SGLT2 inhibitors tied to hypovolemia risk in patients with type 2 diabetes: Study Medha Baranwal9 Dec 2022 10:30 AM ISTChina: A meta-analysis published in Frontiers in Cardiovascular Medicine has shown that sodium-glucose cotransporter-2 (SGLT2) inhibitors increased...
Which second-line antihyperglycemic drugs are most effective for lowering CKD risk? Medha Baranwal21 Nov 2022 8:00 PM ISTThailand: A recent study published in Cardiovascular Diabetology has compared the treatment effectiveness of sodium-glucose cotransporter-2 inhibitors...
Dapagliflozin benefits Heart failure patients Independent of baseline kidney function: JAMA Dr. Kamal Kant Kohli16 Nov 2022 10:45 AM ISTMassachusetts: According to research published in JAMA Cardiology, baseline renal function did not alter the benefit of dapagliflozin in individuals...
Dapagliflozin effective from clinical standpoint as well as cost standpoint for CKD patients Dr. Kamal Kant Kohli5 Nov 2022 9:30 AM ISTThe burden of chronic kidney disease (CKD) to both healthcare systems and patients is considerable. Dapagliflozin, a sodium-glucose cotransporter-2...
SGLT2 inhibitors exhibit enhanced cardioprotective effect in obese or overweight patients Dr Kartikeya Kohli17 Oct 2022 11:00 AM ISTUSA: The cardioprotective effect associated with sodium-glucose cotransporter-2 inhibitor (SGLT2i) compared with dipeptidyl peptidase-4 inhibitors...
SGLT-2 inhibitors better than DPP-4 inhibitors in frail diabetes patients Dr. Hiral patel9 Aug 2022 12:00 PM ISTAustralia: Sodium-glucose cotransporter-2 inhibitors may be preferred to dipeptidyl peptidase-4 inhibitors for reducing rates of major adverse...
SGLT 2 inhibitors provide kidney, cardiovascular benefits for diabetes patients Dr. Nandita Mohan13 Nov 2021 2:59 PM ISTIn addition to lowering blood sugar levels, diabetes drugs called Sodium-glucose cotransporter 2 (SGLT2) inhibitors can provide kidney- and...
Risk: Benefit Profile of Sodium-Glucose Cotransporter 2 Inhibitors: JCEM Dr Kartikeya Kohli17 May 2021 11:30 AM ISTSodium-glucose cotransporter 2 inhibitors (SGLT2i) are first-line antidiabetic agents with demonstrated cardiovascular benefits. In a recent...
